相似文献
1
A poliovirus type 1 neutralization epitope is located within amino acid residues 93 to 104 of viral capsid polypeptide VP1.
EMBO J. 1983;2(11):2019-24. doi: 10.1002/j.1460-2075.1983.tb01694.x.
2
3
Localization of a poliovirus type 1 neutralization epitope in viral capsid polypeptide VP1.
Proc Natl Acad Sci U S A. 1983 Aug;80(16):5080-4. doi: 10.1073/pnas.80.16.5080.
4
Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.
J Gen Virol. 1982 Dec;63(2):487-92. doi: 10.1099/0022-1317-63-2-487.
5
Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1.
J Virol. 1991 Feb;65(2):711-8. doi: 10.1128/JVI.65.2.711-718.1991.
6
Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
Nature. 1983;304(5925):459-62. doi: 10.1038/304459a0.
7
Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.
Arch Virol. 1985;83(3-4):295-303. doi: 10.1007/BF01309924.
8
Mapping of antigenic domains in poliovirus VP1 involved in structural rearrangements during virus morphogenesis and antigenic alterations of the virion.
Virology. 1994 Oct;204(1):27-37. doi: 10.1006/viro.1994.1507.
9
Induction of neutralizing antibodies by type 1 poliovirus VP1 capsid polypeptide.
Dev Biol Stand. 1983;55:185-9.
10
Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.
Proc Natl Acad Sci U S A. 1985 Feb;82(3):910-4. doi: 10.1073/pnas.82.3.910.
引用本文的文献
1
Characteristics of four natural poliovirus type 1 variants with six-nucleotide deletion (2,783-2,788 nt) in the VP1 region.
Microbiol Spectr. 2025 Sep 2;13(9):e0133425. doi: 10.1128/spectrum.01334-25. Epub 2025 Aug 8.
2
Defining the Enterovirus Diversity Landscape of a Fecal Sample: A Methodological Challenge?
Viruses. 2016 Jan 12;8(1):18. doi: 10.3390/v8010018.
3
Conformational shift of a major poliovirus antigen confirmed by immuno-cryogenic electron microscopy.
J Immunol. 2013 Jul 15;191(2):884-91. doi: 10.4049/jimmunol.1202014. Epub 2013 Jun 14.
4
Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602.
Infect Immun. 1998 Jan;66(1):77-82. doi: 10.1128/IAI.66.1.77-82.1998.
5
The region around residue 115 of human bactericidal/permeability-increasing protein is not involved in lipopolysaccharide binding or bactericidal activity. Chemical synthesis and expression of a gene coding for the active domain and characterization of recombinant proteins.
Biochem J. 1994 Mar 15;298 Pt 3(Pt 3):711-8. doi: 10.1042/bj2980711.
6
Genetic insertion and exposure of a reporter epitope in the ferrichrome-iron receptor of Escherichia coli K-12.
J Bacteriol. 1994 Jul;176(14):4250-9. doi: 10.1128/jb.176.14.4250-4259.1994.
7
Analysis of antibody responses to predominant linear epitopes of Theiler's murine encephalomyelitis virus.
J Virol. 1994 May;68(5):3324-33. doi: 10.1128/JVI.68.5.3324-3333.1994.
8
Method to map antigenic determinants recognized by monoclonal antibodies: localization of a determinant of virus neutralization on the feline leukemia virus envelope protein gp70.
Proc Natl Acad Sci U S A. 1984 Jun;81(12):3675-9. doi: 10.1073/pnas.81.12.3675.
9
Replicase gene of coxsackievirus B3.
J Virol. 1984 Sep;51(3):742-6. doi: 10.1128/JVI.51.3.742-746.1984.
10
Vaccination against poliomyelitis: present possibilities and future prospects.
Am J Public Health. 1988 Mar;78(3):304-5. doi: 10.2105/ajph.78.3.304.
本文引用的文献
1
Preparation of iodine-131 labelled human growth hormone of high specific activity.
Nature. 1962 May 5;194:495-6. doi: 10.1038/194495a0.
2
Principles of immunization as applied to poliomyelitis and influenza.
Am J Public Health Nations Health. 1953 Nov;43(11):1384-98. doi: 10.2105/ajph.43.11.1384.
3
Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide.
Nature. 1981 Feb 12;289(5798):593-4. doi: 10.1038/289593a0.
4
Characteristics of guinea-pig immune sera elicited by a synthetic diphtheria toxin oligopeptide.
Mol Immunol. 1982 Dec;19(12):1541-9. doi: 10.1016/0161-5890(82)90265-6.
5
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence.
Nature. 1982 Jul 1;298(5869):30-3. doi: 10.1038/298030a0.
6
Expression of poliovirus capsid polypeptide VP1 in Escherichia coli.
Gene. 1983 Jul;23(1):85-93. doi: 10.1016/0378-1119(83)90219-6.
7
Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.
Proc Natl Acad Sci U S A. 1982 Oct;79(19):5793-7. doi: 10.1073/pnas.79.19.5793.
8
Comparison of the amino acid sequence of the major immunogen from three serotypes of foot and mouth disease virus.
Nucleic Acids Res. 1982 Dec 20;10(24):8285-95. doi: 10.1093/nar/10.24.8285.
9
Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats.
Proc Natl Acad Sci U S A. 1982 Dec;79(23):7518-21. doi: 10.1073/pnas.79.23.7518.
10
Identification of the initiation site of poliovirus polyprotein synthesis.
J Virol. 1982 Jun;42(3):1017-28. doi: 10.1128/JVI.42.3.1017-1028.1982.
Zotero 插件